Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Cuts Target Price to $12
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $6
Piper Sandler Sticks to Its Buy Rating for Fulcrum Therapeutics (FULC)
Leerink Partners Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Cuts Target Price to $6
Fulcrum Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $2 to $14
Fulcrum Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $14
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Fulcrum Therapeutics Analyst Ratings
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $2 to $22
Hold Rating on Fulcrum Therapeutics Amid Phase 3 Drug Failure and Pivot to Sickle Cell Disease Candidate
RBC Downgrades Fulcrum Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $15; Speculative Risk Kept
Fulcrum Therapeutics Price Target Announced at $4.00/Share by Leerink Partners
Fulcrum Therapeutics Cut to Market Perform From Outperform by Leerink Partners
Fulcrum Therapeutics Analyst Ratings